129 related articles for article (PubMed ID: 1634144)
1. Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor.
Perez RP; Handel LM; Hamilton TC
Gynecol Oncol; 1992 Jul; 46(1):82-7. PubMed ID: 1634144
[TBL] [Abstract][Full Text] [Related]
2. Overcoming cis-diamminedichloroplatinum (II) resistance of human ovarian tumor cells by combination treatment with cis-diamminedichloroplatinum (II) and tumor necrosis factor-alpha.
Mizutani Y; Bonavida B
Cancer; 1993 Aug; 72(3):809-18. PubMed ID: 8334635
[TBL] [Abstract][Full Text] [Related]
3. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
4. Factors governing the modulation of vinca-alkaloid resistance in doxorubicin-resistant cells by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D; Schmidt H
Biochem Pharmacol; 1986 Feb; 35(4):673-8. PubMed ID: 3947398
[TBL] [Abstract][Full Text] [Related]
5. Modulation of doxorubicin-induced chromosomal damage by calmodulin inhibitors and its relationship to cytotoxicity in progressively doxorubicin-resistant tumor cells.
Ganapathi R; Grabowski D; Hoeltge G; Neelon R
Biochem Pharmacol; 1990 Oct; 40(7):1657-62. PubMed ID: 2222519
[TBL] [Abstract][Full Text] [Related]
6. Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance.
Ganapathi R; Schmidt H; Grabowski D; Melia M; Ratliff N
Br J Cancer; 1988 Sep; 58(3):335-40. PubMed ID: 3179186
[TBL] [Abstract][Full Text] [Related]
7. In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines.
Perez RP; Perez KM; Handel LM; Hamilton TC
Cancer Chemother Pharmacol; 1992; 29(6):430-4. PubMed ID: 1568285
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line.
Tanaka T; Masuda H; Naito M; Tamai H
Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308
[TBL] [Abstract][Full Text] [Related]
9. Synergistic enhancement of efficacy of platinum drugs with verteporfin in ovarian cancer cells.
Dasari VR; Carey DJ; Gogoi R
BMC Cancer; 2020 Apr; 20(1):273. PubMed ID: 32245422
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin-resistant L1210 mouse leukemia cells. Lack of correlation between cellular doxorubicin levels and expression of resistance.
Ganapathi R; Grabowski D
Biochem Pharmacol; 1988 Jan; 37(2):185-93. PubMed ID: 3342075
[TBL] [Abstract][Full Text] [Related]
11. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells.
Ganapathi R; Kuo T; Teeter L; Grabowski D; Ford J
Mol Pharmacol; 1991 Jan; 39(1):1-8. PubMed ID: 1670962
[TBL] [Abstract][Full Text] [Related]
12. Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity.
Mircheva J; Smith PJ; Bleehen NM
Br J Cancer; 1986 Jan; 53(1):99-103. PubMed ID: 2418860
[TBL] [Abstract][Full Text] [Related]
13. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
14. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
15. Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: II. DNA damage, repair and chromatin changes.
Smith PJ; Mircheva J; Bleehen NM
Br J Cancer; 1986 Jan; 53(1):105-14. PubMed ID: 2418859
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum.
Uslu R; Bonavida B
Cancer; 1996 Feb; 77(4):725-32. PubMed ID: 8616765
[TBL] [Abstract][Full Text] [Related]
19. Calmodulin inhibitor trifluoperazine in combination with doxorubicin induces the selection of tumour cells with the multidrug resistant phenotype.
Kamath N; Grabowski D; Ford J; Ganapathi R
Br J Cancer; 1993 Jun; 67(6):1203-8. PubMed ID: 8099806
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
